WO2016121664A1 - ピロールカルボキサミドの固形組成物 - Google Patents
ピロールカルボキサミドの固形組成物 Download PDFInfo
- Publication number
- WO2016121664A1 WO2016121664A1 PCT/JP2016/051956 JP2016051956W WO2016121664A1 WO 2016121664 A1 WO2016121664 A1 WO 2016121664A1 JP 2016051956 W JP2016051956 W JP 2016051956W WO 2016121664 A1 WO2016121664 A1 WO 2016121664A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- lactose hydrate
- solid composition
- particle size
- pyrrole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to (S) -1- (2-hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -1H-pyrrole- 3-Carboxamide ((S) -1- (2-Hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -1H-pyrrole-3-carboxamide, hereinafter sometimes referred to as "Compound (I)". ) And a method for preparing the stabilized pharmaceutical solid composition.
- the present invention also relates to solid preparations in the form of stabilized tablets, powders, granules and capsules of compound (I), and solid preparations in the form of these stabilized tablets, powders, granules and capsules. It relates to the manufacturing method.
- Compound (I) represented by the formula (1) is disclosed in US Pat. No. 8,524,918 and has excellent activity as a mineralocorticoid receptor (MR) (aldosterone receptor) antagonist.
- MR mineralocorticoid receptor
- Excellent therapeutic and / or preventive effects are expected for diseases such as arteriosclerosis, restenosis after PTCA, and peripheral circulatory disturbance. Furthermore, an effect is expected also in remission of diabetic nephropathy.
- the quality eg content, tablet hardness, It is an important condition to maintain elution and disintegration, and high storage stability over a long period is required.
- the present inventors provide a pharmaceutical solid composition of Compound (I) having enhanced storage stability (chemical and / or physical), and a method for preparing the stabilized pharmaceutical solid composition, , Solid preparations in the form of stabilized tablets, powders, granules and capsules of compound (I), and methods for producing these stabilized preparations in the form of tablets, powders, granules and capsules As a result of earnest research, the present invention was completed by solving the problem.
- a method for producing a solid composition for pharmaceutical use comprising the step of mixing carboxamide and an additive comprising lactose hydrate having an average particle size in the range of 5 to 50 ⁇ m, (8-1) (S) -1- (2-hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -1H-pyrrole -3-This is a method for producing a solid composition
- the present invention overcomes various difficulties to obtain a stabilized pharmaceutical solid composition of Compound (I), and finally obtains the stabilized pharmaceutical solid composition. It has a feature in the points that were made.
- a stabilized pharmaceutical solid composition of Compound (I) can be prepared, and further, stabilized tablets, powders, granules and capsules of Compound (I) can be prepared. It has become possible to produce solid formulations in the form of these, as well as solid formulations in the form of these stabilized tablets, powders, granules and capsules.
- the lactose hydrate used in the present invention is not particularly limited as long as it can be used as a pharmaceutical additive and has an average particle diameter in the range of 5-50 ⁇ m.
- Lactochem (R) Powder, Lactochem (R) Fine Powder, Lactochem (R) Extra Fine Powder, Pharmatose (R) 450M, and Lactohale (R) 201 are suitable.
- the “average particle size” in the present invention means the particle size at an integrated value of 50% in the particle size distribution obtained by a sieving device (for example, “ATM sonic sifter” manufactured by ATM corp).
- the solid preparation of the present invention may further contain excipients other than appropriate pharmacologically acceptable lactose hydrates, lubricants, binders, emulsifiers, stabilizers, flavoring agents, and / or Additives such as disintegrants can be included.
- excipient examples include sugar derivatives such as lactose, lactose hydrate, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch or dextrin; Cellulose derivatives such as crystalline cellulose; gum arabic; dextran; or organic excipients such as pullulan; or silicic acid such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate or magnesium metasilicate aluminate Inorganic excipients such as salt derivatives; phosphates such as calcium hydrogen phosphate; carbonates such as calcium carbonate; or sulfates such as calcium sulfate can be mentioned.
- sugar derivatives such as lactose, lactose hydrate, sucrose, glucose, mannitol or sorbitol
- starch derivatives such as corn starch, potato starch, ⁇ -starch or dextrin
- Cellulose derivatives such as crystalline
- excipients selected from sugar derivatives Preferably, lactose, a lactose hydrate, one or more excipients selected from other crystalline and crystalline cellulose mannitol, and most preferably lactose hydrate.
- Lubricants used include, for example, stearic acid; metal stearates such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or whale wax; boric acid; adipine Acids; sulfates such as sodium sulfate; glycols; fumaric acid; sodium stearyl fumarate; sucrose fatty acid esters; sodium benzoate; D, L-leucine; lauryl sulfates such as sodium lauryl sulfate or magnesium lauryl sulfate; Silicic acids such as silicic acid or silicic acid hydrate; or the above-mentioned starch derivatives and the like can be mentioned, and metal stearates are preferred.
- binder examples include hydroxypropyl cellulose, hypromellose, polyvinyl pyrrolidone, polyethylene glycol, and the same compounds as the above-mentioned excipients, preferably hydroxypropyl cellulose or hypromellose. is there.
- Emsifiers used include, for example, colloidal clays such as bentonite or bee gum; metal hydroxides such as magnesium hydroxide or aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate or calcium stearate A cationic surfactant such as benzalkonium chloride; or a nonionic surfactant such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester or sucrose fatty acid ester.
- colloidal clays such as bentonite or bee gum
- metal hydroxides such as magnesium hydroxide or aluminum hydroxide
- anionic surfactants such as sodium lauryl sulfate or calcium stearate
- a cationic surfactant such as benzalkonium chloride
- a nonionic surfactant such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester or sucrose fatty acid ester.
- “Stabilizers” used include, for example, paraoxybenzoates such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenol or cresol Phenols; thimerosal; dehydroacetic acid; or sorbic acid.
- sweeteners such as sodium saccharin or aspartame
- acidifiers such as citric acid, malic acid or tartaric acid
- flavorings such as menthol, lemon or orange. Can do.
- Disintegrants used include, for example, cellulose derivatives such as low substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium or sodium carboxymethylcellulose; crosslinked polyvinylpyrrolidone; or carboxymethyl starch or carboxymethyl starch Examples thereof include starch and cellulose modified chemically such as sodium.
- the compounding amount of the compound having the above general formula (I) or a pharmacologically acceptable salt thereof in the solid preparation is not particularly limited, but for example, 0.1 to 10.0% by weight relative to the total weight of the solid preparation It is preferable to blend (preferably 0.1 to 5.0% by weight).
- the amount of the additive in the total amount of the solid preparation is not particularly limited.
- the excipient is contained in an amount of 10.0 to 93.5% by weight including lactose hydrate with respect to the total weight of the solid preparation. (Preferably 44.0-90.0% by weight), lubricant 0.5-5.0% by weight (preferably 0.5-3.0% by weight), and binder 0. 0 to 15.0 wt% (preferably 1.0 to 5.0 wt%), disintegrant 2.5 to 40.0 wt% (preferably 5.0 to 30.0 wt%) It is preferable to mix.
- the solid preparation of the present invention includes, for example, tablets (including sublingual tablets and orally disintegrating agents), capsules (including soft capsules and microcapsules), granules, fine granules, powders, pills, chewable agents, and troches. It is preferably a powder, fine granule, granule, capsule or tablet, and most preferably a tablet.
- the solid preparation of the present invention is a powder of the active ingredient compound (I), (1) Add stabilizers, such as excipients and disintegrants, and further aids (lubricants, etc.) necessary for formulation, (2) Capsule filling step of compressing and filling the obtained granular powder with a capsule filling machine, or tableting step of compressing the obtained granular powder with a tableting machine, and granular powder and granules obtained as necessary Or it can obtain as a powder, a granule, a surface coat granule, a capsule, a tablet, and a surface coat tablet by carrying out the coating process which coats the surface of a tablet one by one.
- the production method for solid preparations is as follows: (1) A direct compression method in which active ingredients and additives are mixed, and compression-molded directly with a tableting machine; Direct compression method, (3) Dry granulation method in which active ingredients and additives are granulated by dry method, and then added with lubricant etc., then compression molding, (4) Wet active ingredients and additives Examples thereof include a wet granule compression method in which a granule is granulated by a method and then a lubricant is added to the granule, followed by compression molding.
- a granulation method means, such as a fluidized granulation method, a high speed stirring granulation method, a melting granulation method (melting granulation), can be used.
- a method of preparing a tablet by granulating an active ingredient and an additive as a granule by a wet method and then adding a lubricant or the like to the granule is preferable.
- the manufacturing method of the tablet of the present invention is as described below.
- an excipient, a binder and / or a disintegrant are granulated by a wet method. Thereafter, the granules are sieved with a granulator, a lubricant is added, and the mixture is further mixed, and then tableted with a tableting machine to obtain tablets.
- Coating is performed using, for example, a film coating apparatus.
- the film coating base include sugar coating base, water-soluble film coating base, enteric film coating base, sustained-release film coating base, and the like. Can be mentioned.
- sucrose is used, and one or more kinds selected from talc, precipitated calcium carbonate, calcium phosphate, calcium sulfate, gelatin, gum arabic, polyvinylpyrrolidone, pullulan and the like can be used in combination. .
- water-soluble film coating bases examples include cellulose derivatives such as hydroxypropylcellulose, hypromellose, hydroxyethylcellulose, methylhydroxyethylcellulose or sodium carboxymethylcellulose; synthetic polymers such as polyvinyl acetal diethylaminoacetate, aminoalkylmethacrylate copolymer or polyvinylpyrrolidone. A molecule; or a polysaccharide such as pullulan.
- enteric film coating bases include cellulose derivatives such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose or cellulose acetate phthalate; (meth) acrylic acid copolymer L, (meth) acrylic acid Examples thereof include acrylic acid derivatives such as copolymer LD or (meth) acrylic acid copolymer S; or natural products such as shellac.
- sustained-release film coating base examples include cellulose derivatives such as ethyl cellulose; or acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS or ethyl acrylate / methyl methacrylate / copolymer emulsion. be able to.
- the above coating bases may be used as a mixture of two or more thereof in an appropriate ratio. Furthermore, additives such as appropriate pharmacologically acceptable plasticizers, excipients, lubricants, masking agents, coloring agents and / or preservatives can be further included as necessary.
- plasticizer that can be used in the present invention is not particularly limited, and can be appropriately selected by those skilled in the art.
- plasticizers include propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, diethyl phthalate and triethyl citrate, lauric acid, sucrose, dextrose, sorbitol, triacetin, and acetyl triethyl titrate. , Triethyl titrate, tributyl titrate, acetyl tributyl titrate and the like.
- Examples of the concealing agent that can be used in the present invention include titanium oxide.
- Examples of the colorant that can be used in the present invention include iron sesquioxide, yellow iron sesquioxide, black iron oxide, titanium oxide, blue No. 1 (Brilliant Blue FCF), blue No. 2 (Indigo carmine), and red No. 3 (Erythrosine). ), Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF), and the like.
- ferric sesquioxide Preferred are iron sesquioxide, yellow ferric oxide, and black ferric oxide, and more preferred are ferric sesquioxide and yellow ferric oxide.
- the content of the colorant used in the present invention is preferably 0.01 to 1% by weight (more preferably 0.02% to 0.1% by weight) based on the total weight of the uncoated tablet when included in the uncoated tablet component.
- it is preferably added in an amount of 0.003 to 0.1% by weight (more preferably 0.01% to 0.1% by weight) based on the total weight of the uncoated tablet.
- preservatives examples include parabens.
- the dose of the compound having the above general formula (I) or a pharmacologically acceptable salt thereof, which is an active ingredient of the solid preparation of the present invention varies depending on various conditions such as drug activity, patient symptoms, age or body weight. Can do. In the case of oral administration, the dose is usually 0.010 mg (preferably 0.625 mg) as the lower limit for adults, and 100.0 mg (preferably 30.0 mg) as the upper limit. Can be administered. (Method for producing solid preparation) Next, the present invention will be described in more detail with reference to examples and the like. However, the following examples are for explaining the present invention, and the present invention should not be limited to these examples. .
- Example 1 Lactose Hydrate Particle Size and Formulation Stability (1-1) Tablet Production Method For each lactose hydrate shown in Table 1, compound (I), lactose hydrate, low degree of substitution Weigh hydroxypropylcellulose (LH-21, Shin-Etsu Chemical), hydroxypropylcellulose (HPC-L, Nippon Soda) and yellow iron sesquioxide (Hana Kasei) at a blending ratio according to the composition shown in Table 2, and with purified water After putting into a high-speed stirring granulator (VG-5 or VG-10, Powrec), the mixture was kneaded for 3 minutes at a blade rotation speed of 280 or 250 rpm to obtain a granulated powder.
- VG-5 or VG-10, Powrec high-speed stirring granulator
- This granulated powder is dried with a fluidized bed dryer (NFLO-2, POWREC or FLO-5M, Freund Industries) until the product temperature reaches 60 ° C, and then comil (QC-197 or QC-194S, ⁇ 1.143) (mm, QUADRO) and sieved at 2200 rpm to obtain granulated granules.
- the granulated granules and magnesium stearate were charged into a V-type mixer (2 L) so that the mass mixing ratio was 99: 1 and mixed for 5 minutes at a rotation speed of 39 rpm.
- the average particle size of lactose hydrate is the value described in the catalog measured by the dry sieving method (ATM sonic sifter, ATMAcorp.).
- Example (1-1) Evaluation method and results Regarding the tablets produced in Example (1-1) (tablets a to e using each of lactose hydrates 1 to 4), the following environmental conditions for accelerating the deterioration of the tablets A disintegration test and a dissolution test were conducted to compare the tablets that had passed through the storage process (storage A) in (with storage A) and the tablets that did not pass through storage A (control).
- the dissolution test was evaluated according to the dissolution test method (paddle method, 50 rpm) of the 16th revised Japanese Pharmacopeia, using 900 ml of 0.1% polysorbate 80 (TW-O120V, Kao) aqueous solution as the test solution.
- the disintegration test was evaluated without an auxiliary panel according to the 16th revised Japanese Pharmacopoeia disintegration test method.
- the average particle size of lactose hydrate is the value described in the catalog measured by the dry sieving method (ATM sonic sifter, ATMAcorp.).
- the dissolution rate for tablets d and e (at 15 minutes and 30 minutes) decreased by more than 20% for tablets after storage A, but almost unchanged for tablets a, tablets b, and tablets c. Did not occur.
- Example 2 Stability of a preparation by adding a colorant (2-1) Tablet production method
- Compound (I) lactose hydrate (Pharmatose 450M, DFE Pharma), low-substituted hydroxypropylcellulose (LH-21, Shin-Etsu Chemical), hydroxypropylcellulose (HPC-L, Japan) Soda) and yellow iron sesquioxide (Hana Kasei) were weighed in proportions according to the composition shown in Table 4 and charged into a high-speed agitation granulator (VG-10, Powrec) with purified water, followed by a blade rotation speed of 250 rpm.
- VG-10 high-speed agitation granulator
- a granulated powder is dried with a fluidized bed dryer (FLO-5M, Freund Industries) until the product temperature reaches 60 ° C, and then at 2200 rpm using a Comil (QC-194S, ⁇ 1.143 mm, QUADRO). Sieving to obtain sized granules.
- the sized granules and magnesium stearate were charged into a V-type mixer (5 L) so that the mass mixing ratio was 99: 1 and mixed for 5 minutes at a rotation speed of 34 rpm.
Abstract
Description
((S)-1-(2-Hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]
-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide、以下、「化合物(I)」と称することがある。)の保存安定性の高い医薬用の固形組成物、およびその安定化された医薬用の固形組成物の調製方法に関する。
次の構造式:
(1)以下の式(I)を有する化合物である(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミド
(2)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5-50 μmの範囲内である乳糖水和物を混合して存在させることにより、(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドの溶出低下が防止されたことを特徴とする、医薬用の固形組成物、
(2-1)第16改正日本薬局方の溶出試験法(パドル法)において、試験時間30分時点の溶出低下が防止された、上記(2)に記載の医薬用の固形組成物、
(2-2)(i) 蓋無し褐色瓶の開放系にて40℃75%RH環境下に二日間保管、
(ii) (i)の保管後に褐色瓶の蓋を固く閉じ、60℃湿度成り行き環境下に1週間保管、
(i)及び(ii)の工程後、第16改正日本薬局方の溶出試験法(パドル法)において、試験開始から30分時点の溶出低下が防止された、上記(2)に記載の医薬用の固形組成物、
(3)乳糖水和物が、平均粒子径15~50 μmの範囲内の乳糖水和物である、上記(1)又は(2)に記載の医薬用の固形組成物、
(4)乳糖水和物が、平均粒子径が15~40 μmの範囲内の乳糖水和物である、上記(1)又は(2)に記載の医薬用の固形組成物、
(5)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50 μmの範囲内である乳糖水和物を混合して存在させることにより、崩壊時間の遅延を防止することを特徴とする、医薬用の固形組成物、
(5-1)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50 μmの範囲内の乳糖水和物を混合して存在させることにより、崩壊時間の遅延を防止することを特徴とする、溶出低下が防止された医薬用の固形組成物、
(5-2)さらに、低置換度ヒドロキシプロピルセルロース及びヒドロキシプロピルセルロースを含有する上記(1)~(5-1)から選択されるいずれか1つに記載の医薬用の固形組成物、
(5-3)さらに、ステアリン酸マグネシウムを含有する上記(1)~(5-2)から選択されるいずれか1つに記載の医薬用の固形組成物、
(5-4)さらに着色剤を混合して存在させるか又は、コーティング部に着色剤を存在させることにより、安定性が向上した上記(1)~(5-3)から選択されるいずれか1つに記載の医薬用の固形組成物、
(6)崩壊時間が10分以内である、上記(5)に記載の医薬用の固形組成物、
(7)医薬用の固形組成物が錠剤である、上記(1)~(6)から選択されるいずれか1つに記載の医薬用の固形組成物、
(8)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物を含む添加剤を混合する工程を含む、医薬用の固形組成物の製法、
(8-1)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物を含む添加剤を混合する工程を含むことにより溶出低下が防止された、医薬用の固形組成物の製法である、上記(8)に記載の製法、
(8-2)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物を含む添加剤を混合する工程を含むことにより崩壊時間の遅延が防止された、医薬用の固形組成物の製法である、上記(8)に記載の製法、
(9)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルセルロース及び着色剤を湿式法で造粒する工程及び、
ステアリン酸マグネシウムを加えて圧縮成型する工程、
を含む上記(8)に記載の製法、
(9-1)さらにコーティング工程を含む、上記(9)に記載の製法、
(10)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物、低置換度ヒドロキシプロピルセルロース及びヒドロキシプロピルセルロースを湿式法で造粒する工程及び、
ステアリン酸マグネシウムと着色剤を加えて圧縮成型する工程、
を含む上記(8)に記載の製法、
(10-1)さらにコーティング工程を含む、上記(10)に記載の製法、
(11)(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物、低置換度ヒドロキシプロピルセルロース及びヒドロキシプロピルセルロースを湿式法で造粒する工程及び、
ステアリン酸マグネシウムを加えて圧縮成型する工程、
着色剤を含むコーティング剤によるコーティング工程、
を含む上記(8)に記載の製法、
(12)着色剤が、黄色三二酸化鉄及び/又は三二酸化鉄である、上記(9)~(11)に記載の製法、
である。
(1)安定化剤である賦形剤及び崩壊剤等、さらに製剤化に必要な助剤(滑沢剤等)を添加して、
(2)得られた粒状粉末をカプセル充填機によって圧縮充填するカプセル充填工程、または、得られた粒状粉末を打錠機によって圧縮する錠剤化工程、そして必要に応じて得られた粒状粉末、顆粒または錠剤の表面をコーティングするコーティング工程
を順次おこなうことによって、散剤、顆粒剤、表面コート顆粒剤、カプセル剤、錠剤、表面コート錠剤として得られるものである。
ついで本発明を実施例等によって更に詳細に説明するが、以下の実施例は本発明を説明するためのものであって、本発明をこれら実施例に限定して解してはならないものとする。
(1-1)錠剤の製造方法
表1に示す各乳糖水和物について、化合物(I)、乳糖水和物、低置換度ヒドロキシプロピルセルロース(LH-21、信越化学)、ヒドロキシプロピルセルロース(HPC-L、日本曹達)及び黄色三二酸化鉄(癸巳化成)を表2に示す組成に応じた配合比率で量り取り、精製水とともに高速撹拌造粒機(VG-5又はVG-10、パウレック)に投入後、ブレード回転数280又は250 rpmで3分間練合し、造粒末を得た。この造粒末を流動層乾燥機(NFLO-2、パウレック又はFLO-5M、フロイント産業)で製品温度が60℃となるまで乾燥し、その後、コーミル(QC-197又はQC-194S、Φ1.143 mm、QUADRO)を用いて2200 rpmで篩過し、整粒顆粒を得た。この整粒顆粒とステアリン酸マグネシウムを質量混合比率が99:1となるようV型混合機(2 L)に投入し、回転数39 rpmにて5分混合した。これを打錠機(Correct 18HUK、菊水製作所)を用いて、錠剤質量を200 mgとし、打錠圧10kNにて成型することでφ-8.0mmの素錠を得た。得られた素錠に、コーティング機(ハイコータラボ30、フロイント)を用いて給気温度75℃、スプレー速度3 g/minでフィルムコーティングを施した。
実施例(1-1)で製造した錠剤(乳糖水和物1~4それぞれを使用した錠剤a~e)について、錠剤の劣化を加速させる以下の環境条件下での保管プロセス(保管A)を経た錠剤(保管Aあり)と、保管Aを経ていない錠剤(対照)とを比較する崩壊試験および溶出試験を実施した。
(実施例2)着色剤添加による製剤の安定性
(2-1)錠剤の製造方法
化合物(I)、乳糖水和物(Pharmatose 450M, DFE ファーマ)、低置換度ヒドロキシプロピルセルロース(LH-21、信越化学)、ヒドロキシプロピルセルロース(HPC-L、日本曹達)及び黄色三二酸化鉄(癸巳化成)を表4に示す組成に応じた配合比率で量り取り、精製水とともに高速撹拌造粒機(VG-10、パウレック)に投入後、ブレード回転数250 rpmで3分間練合し、造粒末を得た。この造粒末を流動層乾燥機(FLO-5M、フロイント産業)で製品温度が60℃となるまで乾燥し、その後、コーミル(QC-194S、Φ1.143 mm、QUADRO)を用いて2200 rpmで篩過し、整粒顆粒を得た。この整粒顆粒とステアリン酸マグネシウムを質量混合比率が99:1となるようV型混合機(5 L)に投入し、回転数34 rpmにて5分混合した。これを打錠機(Correct 18HUK、菊水製作所)を用いて、錠剤質量を200 mgとし、打錠圧10kNにて成型することでφ-8.0mmの素錠を得た。得られた素錠に、コーティング機(ドリアコータ200、フロイント)を用いて給気温度75℃、スプレー速度3 g/minでフィルムコーティングを施した。
(2-1)で製造した錠剤を、25℃/60%RH/25日(2000Lux/時)開放条件で放置した後、類縁物量をHPLC(1290 Infinity、Agilent)を用いて表5に示す条件で測定した。
Claims (10)
- (S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内である乳糖水和物を混合して存在させることにより、(S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドの溶出低下が防止されたことを特徴とする、医薬用の固形組成物。
- 乳糖水和物が、平均粒子径15~50 μmの範囲内の乳糖水和物である、請求項1又は2に記載の医薬用の固形組成物。
- 乳糖水和物が、平均粒子径15~40 μmの範囲内の乳糖水和物である、請求項1又は2に記載の医薬用の固形組成物。
- (S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50 μmの範囲内である乳糖水和物を混合して存在させることにより、崩壊時間の遅延を防止することを特徴とする、医薬用の固形組成物。
- 崩壊時間が10分以内である、請求項5に記載の医薬用の固形組成物。
- 医薬用の固形組成物が錠剤である、請求項1乃至6から選択されるいずれか1つに記載の医薬用の固形組成物。
- (S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物を含む添加剤を混合する工程を含む、医薬用の固形組成物の製法。
- (S)-1-(2-ヒドロキシエチル)-4-メチル-N-[4-(メチルスルホニル)フェニル]-5-[2-(トリフルオロメチル)フェニル]-1H-ピロール-3-カルボキサミドと、平均粒子径が5~50μmの範囲内の乳糖水和物、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルセルロース及び着色剤を湿式法で造粒する工程及び、
ステアリン酸マグネシウムを加えて圧縮成型する工程、
を含む、請求項8に記載の製法。 - 着色剤が、黄色三二酸化鉄又は三二酸化鉄である、請求項9に記載の製法。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112017015788-8A BR112017015788B1 (pt) | 2015-01-26 | 2016-01-25 | Composição sólida, e, método de fabricação para uma composição sólida |
EP16743267.3A EP3251669B1 (en) | 2015-01-26 | 2016-01-25 | Solid composition of pyrrole carboxamide |
KR1020177019890A KR102488167B1 (ko) | 2015-01-26 | 2016-01-25 | 피롤카르복사미드의 고형 조성물 |
CA2973944A CA2973944C (en) | 2015-01-26 | 2016-01-25 | Solid composition of pyrrole carboxamide |
ES16743267T ES2832465T3 (es) | 2015-01-26 | 2016-01-25 | Composición sólida de pirrol carboxamida |
CN201680007114.6A CN107205984B (zh) | 2015-01-26 | 2016-01-25 | 吡咯甲酰胺的固体组合物 |
JP2016571999A JP6707471B2 (ja) | 2015-01-26 | 2016-01-25 | ピロールカルボキサミドの固形組成物 |
US15/660,625 US10034855B2 (en) | 2015-01-26 | 2017-07-26 | Solid composition of pyrrole carboxamide |
HK18107273.3A HK1247826A1 (zh) | 2015-01-26 | 2018-06-04 | 吡咯甲酰胺的固體組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-012252 | 2015-01-26 | ||
JP2015012252 | 2015-01-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/660,625 Continuation US10034855B2 (en) | 2015-01-26 | 2017-07-26 | Solid composition of pyrrole carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016121664A1 true WO2016121664A1 (ja) | 2016-08-04 |
Family
ID=56543277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/051956 WO2016121664A1 (ja) | 2015-01-26 | 2016-01-25 | ピロールカルボキサミドの固形組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10034855B2 (ja) |
EP (1) | EP3251669B1 (ja) |
JP (1) | JP6707471B2 (ja) |
KR (1) | KR102488167B1 (ja) |
CN (1) | CN107205984B (ja) |
BR (1) | BR112017015788B1 (ja) |
CA (1) | CA2973944C (ja) |
ES (1) | ES2832465T3 (ja) |
HK (1) | HK1247826A1 (ja) |
TW (1) | TWI686195B (ja) |
WO (1) | WO2016121664A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010111657A (ja) * | 2008-10-07 | 2010-05-20 | Daiichi Sankyo Co Ltd | ピロール誘導体のアトロプ異性体を含有する医薬 |
JP2014088454A (ja) * | 2014-02-21 | 2014-05-15 | Dainippon Sumitomo Pharma Co Ltd | 光安定性の向上した組成物 |
JP2014162769A (ja) * | 2013-02-26 | 2014-09-08 | Nipro Corp | 医薬組成物 |
JP2015007116A (ja) * | 2012-10-12 | 2015-01-15 | 味の素株式会社 | カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3506276C1 (de) * | 1985-02-22 | 1986-04-24 | Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring | Direkttablettiermittel |
FR2752162B1 (fr) * | 1996-08-07 | 1998-11-06 | Jouveinal Lab | Comprime de maleate de trimebutine pellicule |
AU2005265031A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
WO2006012642A2 (en) * | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
JP5363312B2 (ja) * | 2007-04-09 | 2013-12-11 | 第一三共株式会社 | ピロール誘導体のアトロプ異性体 |
EP2359813A1 (en) * | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
JP6027911B2 (ja) * | 2013-02-18 | 2016-11-16 | フロイント産業株式会社 | 賦形剤造粒物及びその製造方法、並びに錠剤 |
-
2016
- 2016-01-25 CA CA2973944A patent/CA2973944C/en active Active
- 2016-01-25 EP EP16743267.3A patent/EP3251669B1/en active Active
- 2016-01-25 CN CN201680007114.6A patent/CN107205984B/zh active Active
- 2016-01-25 KR KR1020177019890A patent/KR102488167B1/ko active IP Right Grant
- 2016-01-25 JP JP2016571999A patent/JP6707471B2/ja active Active
- 2016-01-25 ES ES16743267T patent/ES2832465T3/es active Active
- 2016-01-25 WO PCT/JP2016/051956 patent/WO2016121664A1/ja active Application Filing
- 2016-01-25 BR BR112017015788-8A patent/BR112017015788B1/pt active IP Right Grant
- 2016-01-26 TW TW105102294A patent/TWI686195B/zh active
-
2017
- 2017-07-26 US US15/660,625 patent/US10034855B2/en active Active
-
2018
- 2018-06-04 HK HK18107273.3A patent/HK1247826A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010111657A (ja) * | 2008-10-07 | 2010-05-20 | Daiichi Sankyo Co Ltd | ピロール誘導体のアトロプ異性体を含有する医薬 |
JP2015007116A (ja) * | 2012-10-12 | 2015-01-15 | 味の素株式会社 | カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤 |
JP2014162769A (ja) * | 2013-02-26 | 2014-09-08 | Nipro Corp | 医薬組成物 |
JP2014088454A (ja) * | 2014-02-21 | 2014-05-15 | Dainippon Sumitomo Pharma Co Ltd | 光安定性の向上した組成物 |
Non-Patent Citations (2)
Title |
---|
DFE PHARMA: "DFE Pharma no Nyuto Seihin", SEIHIN CATALOG, 2013, pages 1 - 10, XP009504748, Retrieved from the Internet <URL:http://www.dfepharma.jp/ja-jp/downloads.aspx?id=%7BCEOB81DC-9BD8-408E-8F13-A184F2F2893D%7D> [retrieved on 20160222] * |
HIRONOBU KATO ET AL.: "Study on the Adaptation of the Standard Formulation to the Direct Compression Method (2) : Effect of Particle Size of Materials", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, vol. 66, no. 5, 2006, Japan, pages 370 - 379, XP009504745, ISSN: 0372-7629 * |
Also Published As
Publication number | Publication date |
---|---|
BR112017015788A2 (ja) | 2018-03-27 |
TWI686195B (zh) | 2020-03-01 |
CN107205984A (zh) | 2017-09-26 |
EP3251669B1 (en) | 2020-09-02 |
KR102488167B1 (ko) | 2023-01-12 |
JP6707471B2 (ja) | 2020-06-10 |
TW201630601A (zh) | 2016-09-01 |
KR20170104486A (ko) | 2017-09-15 |
US10034855B2 (en) | 2018-07-31 |
CN107205984B (zh) | 2019-11-12 |
BR112017015788B1 (pt) | 2023-05-16 |
ES2832465T3 (es) | 2021-06-10 |
EP3251669A1 (en) | 2017-12-06 |
HK1247826A1 (zh) | 2018-10-05 |
JPWO2016121664A1 (ja) | 2017-11-02 |
EP3251669A4 (en) | 2018-07-25 |
CA2973944A1 (en) | 2016-08-04 |
US20170319544A1 (en) | 2017-11-09 |
CA2973944C (en) | 2019-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4868695B2 (ja) | 崩壊性が良好な経口製剤 | |
TWI415635B (zh) | 加衣錠片調製物及製備彼之方法 | |
JP5401327B2 (ja) | 溶出性の改善された錠剤 | |
WO2017170854A1 (ja) | 有効成分の化学的安定性に優れたフィルムコーティング錠 | |
WO2019151405A1 (ja) | 錠剤及びその製造方法 | |
WO2020111089A1 (ja) | 医薬組成物 | |
JP6707471B2 (ja) | ピロールカルボキサミドの固形組成物 | |
JP2010001242A (ja) | レバミピド固形製剤及びその製造方法 | |
JP4808612B2 (ja) | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 | |
KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
JP6077459B2 (ja) | 固形製剤 | |
JP2022042886A (ja) | アビラテロン酢酸エステル含有製剤 | |
NZ583039A (en) | Stable pharmaceutical composition of a water-soluble vinorelbine salt | |
JP6673798B2 (ja) | カペシタビンを有効成分とするフィルムコート医薬製剤 | |
JP2017132724A (ja) | アムロジピン含有被覆造粒物を含む配合口腔内崩壊錠 | |
WO2024084496A1 (en) | Pharmaceutical compositions comprising acalabrutinib maleate | |
WO2023149546A1 (ja) | 経口固形製剤 | |
JP2020189815A (ja) | デュロキセチン製剤およびその安定化方法 | |
AU2020282348A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
JP2023152768A (ja) | 固形製剤、固形製剤の製造方法、および固形製剤の安定化方法 | |
JP2021070659A (ja) | アビラテロン酢酸エステル含有製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16743267 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016571999 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2016743267 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2973944 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20177019890 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017015788 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112017015788 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170724 |